DESTINY-Breast04 investigates the use of trastuzumab deruxtecan, in the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer (0:10). Dr Judy King (Royal Free Hospital, London, UK) joined touchONCOLOGY to discuss the DESTINY-Breast04 trial results and major highlights in breast cancer presented ASCO 2022. In this interview, Dr King also discusses important data from longer term data presented from DESTINY-Breast03 (1:50), and also the phase 3 TROPiCS-02 trial (03:53), examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer. Dr King also discusses CDK4/6 trial data (cyclin-dependent kinases 4 and 6) (5:04) and overall survival results, and finally she looks at the phase 2 MAINTAIN study (5:36) which demonstrated the potential benefit of continued CDK 4/6 inhibition with hormone therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor.
ASCO 2022 Abstracts discussed in this interview:
- Abstract #LBA3: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study
- A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
- Abstract #LBA1001: Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer
Disclosures: Judy King discloses advisory boards membership and speakers fee honoraria from Roche, BMS, Lilly, Novartis, Pfizer, ExactSciences, Prosigna/Veracyte, Eisai and Astra Zeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Share this Video
Related Videos In Breast Cancer
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, EMSO 2023
Significant advancements in breast cancer research emerged from EMSO this year. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) […]
Trastuzumab duocarmazine in HER2+ metastatic breast cancer – TULIP trial results: Philippe Aftimos, ESMO 2023
The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician’s choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023. Dr. Philippe Aftimos, the study investigator from the Institute Jules Bordet in Belgium, presented the results at the conference and then discussed them […]
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!